Inato

Inato is a France-based startup, operating in the intersection of AI, Health Care, Pharmaceutical, and Machine Learning. Established in 2016, the company's vision is to democratize access to clinical trials by matching research sites to suitable clinical trial protocols. Currently, Inato addresses the imbalance in clinical trial access, where 5% of sites run 70% of the trials, leaving many patients excluded. The platform connects global pharmaceutical companies with a broader range of research sites, enhancing trial accessibility and inclusivity. The latest funding round saw a significant $20.00M Series A investment on 29 March 2023 from notable investors including Cathay Innovation, Obvious Ventures, Lamaison Partners, and Top Harvest Capital. This investment speaks to the growing trust in community research sites, aiming to accelerate drug development and increase patient accessibility. Inato aims to bring trials into communities globally, fostering the efficient development of safe and effective treatments for all.